Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis.
Major stressful life events in adulthood and risk of multiple sclerosis.
Seeing optic neuritis through myopic eyes.
Patient's Perspective: Hard Lessons from a Long Hospital Stay.
[Sexuality of men with neurologic disorders].
Laquinimod CHMP/EMA opinion
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
DMDs Are an Essential Issue But Are They the Only Issue in MS Treatment?
[Posture disorders in patients with multiple sclerosis.]
Using experimental autoimmune encephalomyelitis as a model to study the effect of prenatal stress on fetal programming.
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living.
Is multiple sclerosis a proresolution deficiency disorder?
Prolongation of survival of rat cardiac allografts by T cell vaccination.
Olfactory dysfunction in multiple sclerosis.
Longitudinal extensive transverse myelitis and optic neuritis: the elements for the diagnosis of neuromyelitis optica.
Dual role of Response gene to complement-32 in multiple sclerosis.
A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue.
Effects of the Anti-Multiple Sclerosis Immunomodulator Laquinimod on Anxiety and Depression in Rodent Behavioral Models.
[Gluten-related disorders and demyelinating diseases.]
Strategies for myelin regeneration: lessons learned from development.
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

Pages